News
ACTU
8.11
+1.25%
0.10
Weekly Report: what happened at ACTU last week (0909-0913)?
Weekly Report · 6h ago
Actuate Announces Upcoming Presentation On Initial Data On Elraglusib In Combination With FOLFIRINOX At The AACR Special Conference On Advances In Pancreatic Cancer Research
Benzinga · 7h ago
Actuate Gets FDA Orphan Designation for Elraglusib in Soft Tissue Sarcomas
Dow Jones · 5d ago
ACTUATE RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ELRAGLUSIB FOR TREATMENT OF SOFT TISSUE SARCOMAS
Reuters · 5d ago
Actuate Therapeutics Inc: Correspondence
Press release · 6d ago
Actuate Therapeutics Inc: Correspondence Related to Draft Registration Statement
Press release · 6d ago
Weekly Report: what happened at ACTU last week (0902-0906)?
Weekly Report · 09/09 12:46
ACTUATE THERAPEUTICS OBTAINS COMPLETE RESPONSES AND PROVIDES UPDATE ON CLINICAL TRIAL OF ELRAGLUSIB FOR THE TREATMENT OF RELAPSED/REFRACTORY EWING SARCOMA
Reuters · 09/09 12:00
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Barchart · 09/05 08:10
Weekly Report: what happened at ACTU last week (0826-0830)?
Weekly Report · 09/02 12:50
Weekly Report: what happened at ACTU last week (0819-0823)?
Weekly Report · 08/26 12:46
IPO Roundup: WeRide, Reitar Logtech and more
Seeking Alpha · 08/19 13:26
Weekly Report: what happened at ACTU last week (0812-0816)?
Weekly Report · 08/19 12:25
U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline
Seeking Alpha · 08/17 09:10
BRIEF-Actuate Therapeutics Announces Closing Of IPO
Reuters · 08/14 20:12
Actuate Therapeutics shares rise 6% following $22.4M IPO
Seeking Alpha · 08/13 16:53
Reported Earlier, Actuate Therapeutics Prices $22.4M Initial Public Offering Of 2.8M Common Shares At $8/Share
Benzinga · 08/13 07:52
*Actuate Therapeutics Prices Initial Public Offering of 2.8M Shares at $8.00 Each >ACTU
Dow Jones · 08/13 01:13
*Actuate Therapeutics Is Biopharmaceutical Company Focused on Developing Therapies Difficult to Treat Cancers >ACTU
Dow Jones · 08/13 01:13
ACTUATE THERAPEUTICS INC - TO BEGIN NASDAQ TRADING TOMORROW
Reuters · 08/13 00:27
More
Webull provides a variety of real-time ACTU stock news. You can receive the latest news about Actuate Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACTU
Actuate Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic agents for patients with cancer or inflammatory diseases. The Company focuses on the development of compounds for combination use in carcinomas, including glioblastoma, ovarian, breast and pancreatic cancers. Its lead compound, 9-ING-41, is in preclinical xenograft models of cancers, including both drug sensitive and drug resistant carcinomas.